ClinicalTrials.gg
CompletedNCT00403286Updated Jun 30, 2009

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of Fluticasone Propionate/Formoterol Fumarate and Fluticasone Propionate/Formoterol Fumarate in Chronic Obstructive Pulmonary Disease, sponsored by Dey. Completed at 49 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2009-06-30.

Sponsored by Dey (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 4 under way, 1 of them phase 3. Fluticasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
17th of 59
457 · median 95
Started
2006
with 4 others
Phase 2
10 of 59
none open now
Registered
8th of 59
by date
Lead sponsor
3 of 59
Dey

Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, this one is the 17th largest by enrollment, is one of 5 that started in 2006, is one of 10 in phase 2, and was the 8th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of the study is to determine the appropriate dose of fluticasone propionate/formoterol fumarate that is closest to Advair Diskus (fluticasone propionate/salmeterol xinafoate using pulmonary function, safety, and levels of study drug in blood plasma in patients with chronic obstructive pulmonary disease.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic
  • Obstructive
  • Pulmonary
  • Disease
  • COPD
  • Safety
  • Efficacy
  • Pharmacokinetic
  • Dose-finding
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of
  • Female of to use adequate
  • Smoker or ex-smoker with history of at least 10 years of smoking at least one pack of cigarettes per day
  • Meet lung function requirements

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of asthma
  • Other significant disease than
  • Pregnant or lactating female
  • Female planning to become pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
457 participants (actual)

Study arms

  • Experimental
    C 10/1

    Drug: Fluticasone Propionate/Formoterol Fumarate

  • Experimental
    C 5/2

    Drug: Fluticasone Propionate/Formoterol Fumarate

  • Experimental
    C 5/1

    Drug: Fluticasone Propionate/Formoterol Fumarate

  • Experimental
    FP 1000

    Drug: Fluticasone Propionate

  • Experimental
    FF 20

    Drug: Formoterol Fumarate

  • Active comparator
    AD 250/50

    Drug: Fluticasone Propionate/Salmeterol Xinafoate

  • Placebo comparator
    Plc

    Drug: Placebo

  • Experimental
    C 10/2

    Drug: Fluticasone Propionate/Formoterol Fumarate

Interventions

  • DrugFluticasone Propionate/Formoterol Fumarate

    Drug pages: Fluticasone · Formoterol

    Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks

  • DrugFluticasone Propionate/Formoterol Fumarate

    Drug pages: Fluticasone · Formoterol

    Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks

  • DrugFluticasone Propionate/Formoterol Fumarate

    Drug pages: Fluticasone · Formoterol

    Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks

  • DrugFluticasone Propionate/Formoterol Fumarate

    Drug pages: Fluticasone · Formoterol

    Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks

  • Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks

  • Inhalation Solution for nebulization 20 mcg bid for 2 weeks

  • DrugFluticasone Propionate/Salmeterol Xinafoate

    Drug pages: Fluticasone · Salmeterol Xinafoate

    Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks

  • DrugPlacebo

    Inhalation Solution for nebulization 2 mL bid for 2 weeks

06

What researchers measure

Primary outcomes

  1. 2-hour post-dose FEV1

    Time frame: 2 weeks

  2. AUC(0-12) and Cmax in plasma

    Time frame: 2 weeks

  3. pre-dose FEV1

    Time frame: 2 weeks

  4. Amount and percent total dose excreted in urine

    Time frame: 2 weeks

Secondary outcomes

  1. FEV1 AUC(0-2)

    Time frame: 2 weeks

  2. COPD exacerbations

  3. Treatment Emergent Adverse Events

    Time frame: 2 weeks

07

Study locations

49 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Jasper, Alabama 35501, United States
  • Research Site
    Phoenix, Arizona 85006, United States
  • Research Site
    Buena Park, California 90620, United States
  • Research Site
    Costa Mesa, California 92626, United States
  • Research Site
    Encinitas, California 92024, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    San Diego, California 92120, United States
  • Research Site
    Wheat Ridge, Colorado 80033, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Tamarac, Florida 33321, United States
  • Research Site
    Tampa, Florida 33603, United States
  • Research Site
    Atlanta, Georgia 30309, United States
  • Research Site
    Woodstock, Georgia 30189, United States
  • Research Site
    Coeur d'Alene, Idaho 83814, United States
  • Research Site
    Hines, Illinois 60141, United States
  • Research Site
    Lenexa, Kansas 66219, United States
  • Research Site
    Topeka, Kansas 66606, United States
  • Research Site
    Madisonville, Kentucky 42431, United States
  • Research Site
    Wheaton, Maryland 20902, United States
  • Research Site
    Minneapolis, Minnesota 55402, United States
  • Research Site
    St. Charles, Missouri 63301, United States
  • Research Site
    St. Louis, Missouri 63122, United States
  • Research Site
    Henderson, Nevada 89014, United States
  • Research Site
    Cherry Hill, New Jersey 08003, United States
  • Research Site
    Albuquerque, New Mexico 87108, United States
  • Research Site
    Camillus, New York 13031, United States
  • Research Site
    Liverpool, New York 13088, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Greenville, North Carolina 29615, United States
  • Research Site
    Morrisville, North Carolina 27560, United States
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Cincinnati, Ohio 45227, United States
  • Research Site
    Cincinnati, Ohio 45231, United States
  • Research Site
    Cincinnati, Ohio 45242, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    East Providence, Rhode Island 02914, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Austin, Texas 78750, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    South Burlington, Vermont 05403, United States
  • Research Site
    Abingdon, Virginia 24210, United States
  • Research Site
    Richmond, Virginia 23225, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Milwaukee, Wisconsin 53217, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2006
First posted
Nov 23, 2006
Start
Nov 2006
Primary completionActual
May 2007
CompletionActual
May 2007
Last update
Jun 30, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00403286
Lead sponsor
Dey
First posted
Nov 23, 2006
Start date
Nov 2006
Primary completion
May 2007
Completion
May 2007
Last update
Jun 30, 2009
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Formoterol

Start the discussion